SCA Pharmaceuticals has entered into a definitive membership interest purchase agreement with The Vistria Group and Excellere Capital Management.
The Vistria Group and Excellere Capital Management have purchased all of the issued and outstanding equity interests of SCA Pharma. The cost of the transaction was not disclosed. William Blair & Company served as exclusive financial advisor, and McDermott Will & Emery LLP served as legal counsel to SCA Pharma.
SCA Pharma, an FDA-registered outsourcing facility, recently announced plans to expand both of its two sterile pharmaceutical manufacturing sites in Windsor, Conn., and Little Rock, Ark., after years of continued growth. The expansion will increase SCA Pharma’s physical footprint by more than 50 percent and introduce new automation for current manually operated processes.
“We are very pleased that as we continue our expansion efforts and improvements in our efficiencies, our new partnership with The Vistria Group and Excellere will allow us to accelerate these efforts,” said Milton Boyer, CEO of SCA Pharma. “Both partners recognize the unprecedented growth that we have achieved and are committed to fast-tracking our expansion and automation goals.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
SCA Pharma was previously a portfolio company of Enhanced Healthcare Partners, a healthcare-focused private equity firm.
“We benefitted tremendously from our relationship with Enhanced and are grateful for their insight and support,” Boyer said. “Our growth under their leadership has been phenomenal.”
SCA Pharma’s leadership team will remain, and Boyer will continue to serve in his current capacity as CEO. No changes are planned for the company’s staffing or daily operations.